<p>Corvus Pharmaceuticals（納斯達克代碼：CRVS - 獲取免費報告）在華爾街 Zen 的投資分析師的研究報告中，將其評級從 “賣出” 上調至 “持有”。</p>
<p>獲取 <strong>Corvus Pharmaceuticals</strong> 的提醒：</p>
<p>其他幾位研究分析師最近也對 CRVS 發佈了報告。Weiss Ratings 在 10 月 8 日的研究報告中重申了對 Corvus Pharmaceuticals 股票的 “賣出（d-）” 評級。瑞穗證券在 10 月 29 日的研究報告中對 Corvus Pharmaceuticals 的股票設定了 13.00 美元的目標價。最後，巴克萊在 10 月 13 日的研究報告中開始覆蓋 Corvus Pharmaceuticals 的股票。他們對該股票設定了 “增持” 評級和 16.00 美元的目標價。四位投資分析師對該股票給予了買入評級，一位分析師則給予了賣出評級。根據 MarketBeat.com 的數據，Corvus Pharmaceuticals 目前的平均評級為 “適度買入”，平均目標價為 14.25 美元。</p>
<p><strong>查看我們關於 CRVS 的最新報告</strong></p>
<h2>Corvus Pharmaceuticals 價格表現</h2>
<p>CRVS 的股票在週五開盤價為 7.60 美元。該公司的市值為 5.6757 億美元，市盈率為-14.34，貝塔值為 0.56。Corvus Pharmaceuticals 的股價在過去一年內最低為 2.54 美元，最高為 10.00 美元。該公司的 50 日簡單移動平均線為 6.84 美元，200 日簡單移動平均線為 5.10 美元。</p>
<p>Corvus Pharmaceuticals（納斯達克代碼：CRVS - 獲取免費報告）最近在 11 月 4 日發佈了季度財報。該公司報告每股收益（EPS）為-0.12 美元，超出市場共識預期的-0.14 美元，超出幅度為 0.02 美元。平均而言，賣方分析師預計 Corvus Pharmaceuticals 在當前財政年度的每股收益為-0.63 美元。</p>
<h2>Corvus Pharmaceuticals 的機構交易</h2>
<p>機構投資者和對沖基金最近對該公司的持倉進行了調整。Towerview LLC 在第一季度將其在 Corvus Pharmaceuticals 的股份增加了 64.5%。Towerview LLC 目前擁有 127,500 股該公司的股票，價值 405,000 美元，在此期間又購買了 50,000 股。美國世紀公司在第一季度將其在 Corvus Pharmaceuticals 的持股增加了 103.9%。美國世紀公司目前擁有 89,265 股該公司的股票，價值 284,000 美元，在上個季度又購買了 45,491 股。威靈頓管理集團在第一季度獲得了 Corvus Pharmaceuticals 的新頭寸，價值約為 333,000 美元。Jump Financial LLC 在第一季度購買了 Corvus Pharmaceuticals 的新股份，價值約為 143,000 美元。最後，OMERS ADMINISTRATION Corp 在第一季度將其在 Corvus Pharmaceuticals 的股份增加了 9.0%。OMERS ADMINISTRATION Corp 目前擁有 82,300 股該公司的股票，價值 262,000 美元，在上個季度又購買了 6,800 股。機構投資者持有該公司 46.64% 的股份。</p>
<h2>Corvus Pharmaceuticals 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Corvus Pharmaceuticals, Inc 是一家臨牀階段的生物製藥公司，專注於開發和商業化免疫調節劑產品候選藥物，以治療實體癌症、T 細胞淋巴瘤、自身免疫性疾病、過敏性疾病和傳染病。其主要產品候選藥物是 soquelitinib（CPI-818），這是一種選擇性共價抑制劑，針對白細胞介素 2 誘導的 T 細胞激酶（ITK），目前正在進行多中心的 1/1b 期臨牀試驗，以治療外周 T 細胞淋巴瘤、實體腫瘤和特應性皮炎。</p>
<h2>瞭解更多</h2>
<ul>
<li>我們更看好的五隻股票，勝過 Corvus Pharmaceuticals</li>
<li>如何計算投資回報率（ROI）</li>
<li>OpenAI 的重組可能會成為有史以來最大的 IPO</li>
<li>消費者可選消費股票解析</li>
<li>美國政府不希望失敗的兩隻稀土股票</li>
<li>什麼是股息之王？</li>
<li>CrowdStrike 與 CoreWeave 合作，但投資者拋售消息</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JWUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JWUw"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Corvus Pharmaceuticals 嗎？</h2>
<p>在你考慮投資 Corvus Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦現在購買，以便在更廣泛的市場注意到之前……而 Corvus Pharmaceuticals 並不在名單上。</p>
<p>雖然 Corvus Pharmaceuticals 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

Corvus制藥

<p>華爾街禪在最近的一份報告中將 Corvus Pharmaceuticals（NASDAQ:CRVS）的評級從 “賣出” 上調至 “持有”。其他分析師的觀點各異，Weiss Ratings 維持 “賣出” 評級，而巴克萊則給予 “增持” 評級，目標價為 16.00 美元。Corvus 的市值為 5.6757 億美元，報告的每股收益為（0.12 美元），超出預期。機構投資者持有該股票的 46.64%，當前價格為 7.60 美元，過去一年的價格區間為 2.54 美元至 10.00 美元</p>

<p>Corvus Pharmaceuticals (NASDAQ:CRVS - Get Free Report) was upgraded by investment analysts at Wall Street Zen from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research note issued on Saturday.</p>
<div class="lb-trans"><p>Corvus Pharmaceuticals（納斯達克代碼：CRVS - 獲取免費報告）在華爾街 Zen 的投資分析師的研究報告中，將其評級從 “賣出” 上調至 “持有”。</p>
</div><p>Get <strong>Corvus Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Corvus Pharmaceuticals</strong> 的提醒：</p>
</div><p>Several other research analysts also recently issued reports on CRVS. Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of Corvus Pharmaceuticals in a research report on Wednesday, October 8th. Mizuho set a $13.00 target price on shares of Corvus Pharmaceuticals in a research note on Wednesday, October 29th. Finally, Barclays assumed coverage on shares of Corvus Pharmaceuticals in a research note on Monday, October 13th. They set an &#34;overweight&#34; rating and a $16.00 price target on the stock. Four investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Corvus Pharmaceuticals presently has an average rating of &#34;Moderate Buy&#34; and an average target price of $14.25.</p>
<div class="lb-trans"><p>其他幾位研究分析師最近也對 CRVS 發佈了報告。Weiss Ratings 在 10 月 8 日的研究報告中重申了對 Corvus Pharmaceuticals 股票的 “賣出（d-）” 評級。瑞穗證券在 10 月 29 日的研究報告中對 Corvus Pharmaceuticals 的股票設定了 13.00 美元的目標價。最後，巴克萊在 10 月 13 日的研究報告中開始覆蓋 Corvus Pharmaceuticals 的股票。他們對該股票設定了 “增持” 評級和 16.00 美元的目標價。四位投資分析師對該股票給予了買入評級，一位分析師則給予了賣出評級。根據 MarketBeat.com 的數據，Corvus Pharmaceuticals 目前的平均評級為 “適度買入”，平均目標價為 14.25 美元。</p>
</div><p><strong>View Our Latest Report on CRVS</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 CRVS 的最新報告</strong></p>
</div><h2>Corvus Pharmaceuticals Price Performance</h2>
<div class="lb-trans"><h2>Corvus Pharmaceuticals 價格表現</h2>
</div><p>Shares of CRVS opened at $7.60 on Friday. The company has a market capitalization of $567.57 million, a P/E ratio of -14.34 and a beta of 0.56. Corvus Pharmaceuticals has a one year low of $2.54 and a one year high of $10.00. The business's 50 day simple moving average is $6.84 and its 200-day simple moving average is $5.10.</p>
<div class="lb-trans"><p>CRVS 的股票在週五開盤價為 7.60 美元。該公司的市值為 5.6757 億美元，市盈率為-14.34，貝塔值為 0.56。Corvus Pharmaceuticals 的股價在過去一年內最低為 2.54 美元，最高為 10.00 美元。該公司的 50 日簡單移動平均線為 6.84 美元，200 日簡單移動平均線為 5.10 美元。</p>
</div><p>Corvus Pharmaceuticals (NASDAQ:CRVS - Get Free Report) last issued its quarterly earnings data on Tuesday, November 4th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.02. On average, sell-side analysts anticipate that Corvus Pharmaceuticals will post -0.63 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Corvus Pharmaceuticals（納斯達克代碼：CRVS - 獲取免費報告）最近在 11 月 4 日發佈了季度財報。該公司報告每股收益（EPS）為-0.12 美元，超出市場共識預期的-0.14 美元，超出幅度為 0.02 美元。平均而言，賣方分析師預計 Corvus Pharmaceuticals 在當前財政年度的每股收益為-0.63 美元。</p>
</div><h2>Institutional Trading of Corvus Pharmaceuticals</h2>
<div class="lb-trans"><h2>Corvus Pharmaceuticals 的機構交易</h2>
</div><p>Institutional investors and hedge funds have recently made changes to their positions in the business. Towerview LLC grew its stake in shares of Corvus Pharmaceuticals by 64.5% during the first quarter. Towerview LLC now owns 127,500 shares of the company's stock worth $405,000 after purchasing an additional 50,000 shares during the period. American Century Companies Inc. boosted its holdings in Corvus Pharmaceuticals by 103.9% during the first quarter. American Century Companies Inc. now owns 89,265 shares of the company's stock worth $284,000 after buying an additional 45,491 shares during the last quarter. Wellington Management Group LLP acquired a new position in shares of Corvus Pharmaceuticals during the 1st quarter worth about $333,000. Jump Financial LLC bought a new stake in shares of Corvus Pharmaceuticals in the 1st quarter valued at about $143,000. Finally, OMERS ADMINISTRATION Corp increased its stake in shares of Corvus Pharmaceuticals by 9.0% in the 1st quarter. OMERS ADMINISTRATION Corp now owns 82,300 shares of the company's stock valued at $262,000 after acquiring an additional 6,800 shares during the last quarter. Institutional investors own 46.64% of the company's stock.</p>
<div class="lb-trans"><p>機構投資者和對沖基金最近對該公司的持倉進行了調整。Towerview LLC 在第一季度將其在 Corvus Pharmaceuticals 的股份增加了 64.5%。Towerview LLC 目前擁有 127,500 股該公司的股票，價值 405,000 美元，在此期間又購買了 50,000 股。美國世紀公司在第一季度將其在 Corvus Pharmaceuticals 的持股增加了 103.9%。美國世紀公司目前擁有 89,265 股該公司的股票，價值 284,000 美元，在上個季度又購買了 45,491 股。威靈頓管理集團在第一季度獲得了 Corvus Pharmaceuticals 的新頭寸，價值約為 333,000 美元。Jump Financial LLC 在第一季度購買了 Corvus Pharmaceuticals 的新股份，價值約為 143,000 美元。最後，OMERS ADMINISTRATION Corp 在第一季度將其在 Corvus Pharmaceuticals 的股份增加了 9.0%。OMERS ADMINISTRATION Corp 目前擁有 82,300 股該公司的股票，價值 262,000 美元，在上個季度又購買了 6,800 股。機構投資者持有該公司 46.64% 的股份。</p>
</div><h2>Corvus Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Corvus Pharmaceuticals 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.</p>
<div class="lb-trans"><p>Corvus Pharmaceuticals, Inc 是一家臨牀階段的生物製藥公司，專注於開發和商業化免疫調節劑產品候選藥物，以治療實體癌症、T 細胞淋巴瘤、自身免疫性疾病、過敏性疾病和傳染病。其主要產品候選藥物是 soquelitinib（CPI-818），這是一種選擇性共價抑制劑，針對白細胞介素 2 誘導的 T 細胞激酶（ITK），目前正在進行多中心的 1/1b 期臨牀試驗，以治療外周 T 細胞淋巴瘤、實體腫瘤和特應性皮炎。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>瞭解更多</h2>
</div><ul>
<li>Five stocks we like better than Corvus Pharmaceuticals</li>
<li>How to Calculate Return on Investment (ROI)</li>
<li>OpenAI's Restructuring Sets up What Could Be the Biggest IPO Ever</li>
<li>Consumer Discretionary Stocks Explained</li>
<li>2 Rare Earth Stocks the U.S. Government Doesn’t Want to Fail</li>
<li>What is a Dividend King?</li>
<li>CrowdStrike Partners With CoreWeave But Investors Sell the News</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，勝過 Corvus Pharmaceuticals</li>
<li>如何計算投資回報率（ROI）</li>
<li>OpenAI 的重組可能會成為有史以來最大的 IPO</li>
<li>消費者可選消費股票解析</li>
<li>美國政府不希望失敗的兩隻稀土股票</li>
<li>什麼是股息之王？</li>
<li>CrowdStrike 與 CoreWeave 合作，但投資者拋售消息</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JWUw" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=CRVS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Corvus Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Corvus Pharmaceuticals 嗎？</h2>
</div><p>Before you consider Corvus Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮投資 Corvus Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Corvus Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦現在購買，以便在更廣泛的市場注意到之前……而 Corvus Pharmaceuticals 並不在名單上。</p>
</div><p>While Corvus Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Corvus Pharmaceuticals 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

華爾街禪將 Corvus 製藥（NASDAQ:CRVS）的評級上調至 “持有”